natgillin/translations-raw huggingface dataset:
Replaceable filter arrangement according to claim 1, wherein the replaceable filter device can be connected onto the coupling platform via openings in the coupling platform corresponding with the openings for air or gas inlet (3) and outlet (4) in the ground plane of the replaceable filter device. 
Zamjenjivi uređaj za filtriranje u skladu s patentnim zahtjevom 1, naznačen time, da je zamjenjivi filtarski uređaj prilagođen da bude povezan na platformu za spajanje preko otvora na platformi spojnice koji odgovaraju otvorima za ulaz (3) i izlaz (4) zraka ili plina u donjoj površini zamjenjivog filterskog uređaja.
Replaceable filter device according to anyone of the preceding claims, characterized in that the filter elements (2,2') with filter bed in the longitudinal direction of the filter housing covers 90 to 100%, preferably 95% to 100% of the internal length of the filter housing (1). 
Zamjenjivi uređaj za filtriranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da filterski elementi (2,2 ') s filterskim slojem u uzdužnom smjeru filterskog kućišta pokrivaju od 95% do 100% unutarnje dužine filterskog kućišta (1).
Replaceable filter device according to anyone of the preceding claims, characterized in the connection of the openings for air and gas supply and discharge in the coupling platform's surface and the air or gas inlet and outlet in the ground surface of the filter device is sealed by means of a rubber or plastic joint fittings. 
Zamjenjivi uređaj za filtriranje u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačen time, da su spojni dio otvora za dovod i ispuštanje zraka i plina na spojnoj površini platforme i ulaz i izlaz zraka ili plina u donjoj površini uređaja za filtriranje zabrtvljeni pomoću gumenih ili plastičnih spojnica.
The pharmaceutical composition for use according to claim 4, further comprising a cytokine selected from the group consisting of IL-2, IL-3, IL-6, IL-11, IL-12, IL7, IL15, IL21, granulocyte macrophage colony stimulating factor, alpha, beta or gamma interferon and erythropoietin. 
Farmaceutski pripravak namijenjen upotrebi u liječenju neoplazije prema zahtjevu 20, te navedeni pripravak nadalje sadrži citokin odabran iz skupine koju čine IL-2, IL -3, IL -6, IL -11, IL-12, IL-7, IL -15, IL-21, faktor stimulacije kolonija granulocita i makrofaga, alfa, beta ili gama interferon i eritropoetin.
A dosage unit comprising 20 to 300 mg of a diaminophenothiazinium compound according to any one of claims 1 to 4 and a pharmaceutically acceptable carrier, diluent, or excipient. 
Dozna jedinica, naznačena time, da obuhvaća od 20 do 300 mg spoja diaminofenotiazinija prema zahtjevu 1 ili zahtjevu 2 te farmaceutski prihvatljiv nosač, razrjeđivač ili pomoćno sredstvo.
A drug product for the treatment of a disease state associated with tau protein aggregation in a mammal suffering therefrom, comprising a container labelled or accompanied by a label indicating that the drug product is for the treatment of said disease, the container containing one or more dosage units each comprising at least one pharmaceutically acceptable excipient and, as an active ingredient, an isolated pure diaminophenothiazinium compound according to any one of claims 1 to 4. 
Ljekoviti proizvod, naznačen time, da služi za liječenje bolesnog stanja povezanog s agregacijom tau proteina kod sisavca koji boluje od toga stanja, obuhvaćajući označeni spremnik ili spremnik udružen s oznakom koja pokazuje da taj ljekoviti proizvod služi za liječenje spomenute bolesti, pri čemu spremnik sadrži jednu ili više doznih jedinica od kojih svaka obuhvaća najmanje jedno farmaceutski prihvatljivo pomoćno sredstvo, te kao djelatni sastojak obuhvaća izolirani čisti spoj diaminofenotiazinija prema zahtjevu 1 ili zahtjevu 2.
A liquefied gas treatment system for a vessel, which includes a storage tank (11) storing liquefied natural gas, and an engine (3) using the liquefied natural gas stored in the storage tank as fuel, the liquefied gas treatment system comprising: 
Sustav za obradu ukapljenog plina za plovilo, koje sadrži skladišni spremnik (11) za skladištenje ukapljenog zemnog plina, te motor (3) koji upotrebljava ukapljeni zemni plin uskladišten u skladišnom spremniku kao gorivo, naznačen time što sustav za obradu ukapljenog plina sadrži:
a first stream of boil-off gas, which is generated from the liquefied natural gas in the storage tank (11) and is discharged from the storage tank (11); 
prvu struju otparenog plina, nastalog iz ukapljenog zemnog plina u skladišnom spremniku (11), te ispuštenog iz skladišnog spremnika (11);
The liquefied gas treatment system according to claim 1, wherein the gas component returned to the storage tank (11) is discharged from the storage tank together with the boil-off gas generated in the storage tank and is supplied to the compressor (13,13a,13b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što se plinovitu komponentu vraćenu u skladišni spremnik (11) ispušta iz skladišnog spremnika zajedno s otparenim plinom nastalim u skladišnom spremniku, te šalje u kompresor (13,13a,13b).
The liquefied gas treatment system according to claim 1, wherein the compressor (13,13a,13b) is a multi-stage compressor including a plurality of compression means (14,14a,14b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što je kompresor (13,13a,13b) višestadijski kompresor koji sadrži kompresijskih elemenata (14,14a,14b).
The liquefied gas treatment system according to claim 4, wherein the boil-off gas supplied to the heat exchanger (21) is a boil-off gas compressed while passing through all or part of the plurality of compression means included in the compressor (13,13a,13b). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 4, naznačen time što otpareni plin poslan u izmjenjivač topline (21) je otpareni plin komprimiran prilikom prolaska kroz sve ili dio kompresijskih elemenata koje sadrži kompresor (13,13a,13b).
The liquefied gas treatment system according to claim 1, wherein the compressor includes a first compressor (13a) and a second compressor (13b), and the first stream is branched into the second stream and the third stream after passing through the first compressor. 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 1, naznačen time što kompresor uključuje prvi kompresor (13a) i drugi kompresor (13b), gdje se prva struja se grana u drugu struju i treću struju nakon prolaska kroz prvi kompresor.
The liquefied gas treatment system according to claim 7, wherein the third steam is further compressed in the second compressor (13b) and is supplied to the heat exchanger (21). 
Sustav za obradu ukapljenog plina u skladu s patentnim zahtjevom 7, naznačen time što se treću struju dodatno komprimira u drugom kompresoru (13b) i šalje u izmjenjivač topline (21).
A device according to claim 1 or 2, wherein the tank (22) is provided with an auxiliary hole (28b) that by-passes the valve (27). 
Uređaj u skladu s patentnim zahtjevom 1 ili 2, naznačen time, da je spremnik (22) opremljen pomoćnim otvorom (28b) koji zaobilazi ventil (27).
A device according to claim 4, wherein the first window (30) is provided with a first adjustable gate (31), movable for adjusting the flow section of the first window (30) and hence adjusting the outflow rate of the water from the tank (22). 
Uređaj u skladu s patentnim zahtjevom 4, naznačen time, daje prvi prozor (30) opremljen prvim podesivim vratima (31), pomičnim za podešavanje dijela protoka prvog prozora (30) i na taj način za podešavanje protoka vode iz spremnika (22).
The oligomer of claim 1, wherein oligomerization enhances the affinity for binding VEGF, relative to FLT-1. 
Oligomer prema zahtjevu 1, naznačen time da oligomerizacija poboljšava afinitet za VEGF vezanje, u odnosu na FLT-1.
The oligomer of claim 4, wherein the plurality of monomers have free cysteines and are linked to each other through bis-maleimide PEGs. 
Oligomer prema zahtjevu 4, naznačen time da mnoštvo monomera ima slobodne cisteine i međusobno su vezani preko bis-maleimidih PEG-ova.
The oligomer of claim 9, wherein said amino acid sequence is encoded by the nucleic acid sequence set forth in SEQ ID NO: 2. 
Oligomer prema zahtjevu 9, naznačen time da navedenu sekvencu amino kiseline kodira sekvenca nukleinske kiseline prikazana u SEQ ID NO: 2.
The VEGF antagonist oligomer for use according to claim 15, wherein said disease or disorder is selected from a chronic pain, a pathologic angiogenesis, a cancer, a myocardial angiogenesis, or a vascular permeability disorder; or wherein said oligomer is for use to relieve osteoarthritis pain and/or to protect joint structure. 
Oligomer antagonist VEGF za uporabu prema zahtjevu 15, naznačen time da navedena bolest ili poremećaj je odabran od kronične boli, patološke angiogeneze, raka, angiogeneze miokarda ili poremećaja vaskularne permeabilnosti; ili pri čemu je navedeni oligomer namijenjen za ublažavanje bolova kod osteoartritisa i/ili za zaštitu strukture zglobova.
A sPLA2 hydrolysable liposome for use in the treatment of cancer in humans,wherein the content of anionic lipid is between 20% and 45%, the content of polymer conjugated lipid is between 3% and 6% and the content of neutral lipids is between 40% and 75%, and wherein the anionic lipid is DSPG, the neutral lipid is DSPC and the polymer conjugated lipid is DSPE-PEG, said liposome comprising a small molecule antitumour agent selected from the group consisting of: anthracyclin derivatives, cisplatin, oxaliplatin, carboplatin, picoplatin, doxorubicin, paclitaxel, 5-fluoruracil, exisulind, cis-retinoic acid, suldinac sulphide, methotrexate, bleomycin and vincristine. 
Liposom koji može biti hidroliziran primjenom SPLA2 za upotrebu u liječenju raka kod ljudi, naznačeno time da je udio anionskog lipida između 20% i 45%, udio polimera konjugiranih lipida između 3% i 6%, te udio neutralnih lipida između 40% i 75%, a naznačeno time da je anionski lipid DSPG, neutralni lipid DSPC te polimer konjugiranih lipida DSPE-PEG, navedeni liposom sadrži antitumorski agent male molekule izabranog među grupom koja se sastoji od: derivata antraciklina, cisplatina, oksaliplatina, karboplatina, pikoplatina, doksorubicina, paklitaksela, 5-fluoruracila, eksisulinda, cis-retinske kiseline, suldinak sulfida, metotreksata, bleomicina i vinkristina.
The liposome for use in accordance with claim 1, wherein the liposome is for intravenous administration in form of bolus injection or infusion. 
Liposom za upotrebu prema zahtjevu 1, naznačeno time da je liposom namijenjen za intravenoznu primjenu u obliku bolus injekcije ili infuzije.
The liposome for use in accordance with claim 1 or 2, wherein the small molecule antitumor agent is a platinum based antitumor agent selected from the group consisting of cisplatin, oxaliplatin, picoplatin and carboplatin. 
Liposom za upotrebu prema zahtjevu 1 ili 2, naznačeno time da je antitumorni agent male molekule na bazi platine izabran među grupom koja se sastoji od cisplatina, oksaliplatina, pikoplatina i karboplatina.
An inhalable powder formulation comprising a compound of general formula (II) wherein: 
Formulacija praška za inhalaciju koja sadrži spoj opće formule (II) [image]
A dry powder inhaler according to claim 4, wherein the powder is filled in gelatin, plastic or other capsules, cartridges or blister packs or in a reservoir. 
Suhi prašak za inhalaciju prema patentnom zahtjevu 4, naznačeno time da je prašak punjen u želatinske, plastične ili druge kapsule, patrone ili pakiranja blistera ili u spremnike.
A formulation according to claims 6 or 7 wherein the compound is in solution or in dispersed form. 
Formulacija prema patentnim zahtjevima 6 ili 7, naznačeno time da je spoj u otopini ili u dispergiranom obliku.
A propellant-free inhalable formulation comprising a compound of general formula (II) as defined in claim 1. 
Formulacija za inhaliranje bez propelanta koja sadrži spoj opće formule (II) kako je definiran u patentnom zahtjevu 1.
A formulation according to claim 10 wherein the compounds of the invention are in form of solutions or suspensions in an aqueous, alcoholic or hydroalcoholic medium. 
Formulacija prema patentnom zahtjevu 10, naznačeno time da su spojevi iz izuma u obliku otopina ili suspenzija u vodenom, alkoholnom ili hidroalkoholnom mediju.
A rodent, comprising a replacement of a genomic fragment of a rodent IL-4Ra gene at an endogenous rodent IL-4Ra locus with a genomic fragment of a human IL4-Ra gene to form a humanized IL-4Ra gene comprising the ATG initiation codon of coding exon 1 through coding exon 5 of the human IL-4Ra gene, and coding exons 6-9 of the rodent IL-4Ra gene, wherein the genomic fragment of the rodent IL-4Ra gene comprises the ATG initiation codon of coding exon 1 through coding exon 5 of the rodent IL-4Ra gene, and the genomic fragment of the human IL-4Ra gene comprises the ATG initiation codon of coding exon 1 through coding exon 5 of the human IL-4Ra gene, and wherein expression of the humanized IL-4Ra gene is under control of rodent IL-4Ra regulatory elements at the endogenous rodent IL-4Ra locus. 
Glodavac, naznačen time što sadrži zamjenu genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra genomskim fragmentom gena za ljudski IL4-Ra kako bi se dobilo gen za humanizirani IL-4Ra koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ra sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, te gdje je eksprimiranje gena za humanizirani IL-4Ra pod kontrolom regulacijskih elemenata glodavačkog IL-4Ra na lokusu za endogeni glodavački IL-4Ra.
The rodent of claim 1, wherein the rodent comprises a replacement of a genomic fragment of a rodent IL-4 gene at an endogenous rodent IL-4 locus with a genomic fragment of a human IL-4 gene to form a humanized IL-4 gene, wherein the genomic fragment of the rodent IL-4 gene comprises the ATG initiation codon of exon 1 through exon 4 of the rodent IL-4 gene, and the genomic fragment of the human IL-4 gene comprises the ATG initiation codon of exon 1 through exon 4 of the human IL-4 gene, and wherein expression of the humanized IL-4 gene is under control of rodent IL-4 regulatory elements at the endogenous rodent IL-4 locus. 
Glodavac u skladu s patentnim zahtjevom 1, naznačen time što glodavac sadrži zamjenu genomskog fragmenta gena za glodavački IL-4 na lokusu za endogeni glodavački IL-4 genomskim fragmentom gena za ljudski IL-4 kako bi se dobilo gen za humanizirani IL-4, gdje genomski fragment gena za glodavački IL-4 sadrži početni kodon ATG egzona 1 do egzona 4 gena za glodavački IL-4, a genomski fragment gena za ljudski IL-4 sadrži početni kodon ATG egzona 1 do egzona 4 gena za ljudski IL-4, te gdje je eksprimiranje gena za humanizirani IL-4 pod kontrolom regulacijskih elemenata glodavačkog IL-4 na lokusu za endogeni glodavački IL-4.
A method for making a humanized rodent, comprising replacing a genomic fragment of a rodent IL-4Ra gene at an endogenous rodent IL-4Ra locus with a genomic fragment of a human IL-4Ra gene to form a humanized IL-4Ra gene comprising the ATG initiation codon of coding exon 1 through coding exon 5 of the human IL-4Ra gene, and coding exons 6-9 of the rodent IL-4Ra gene, wherein the genomic fragment of the rodent IL-4Ra gene comprises the ATG initiation codon of coding exon 1 through coding exon 5 of the rodent IL-4Ra gene, and the genomic fragment of the human IL-4Ra gene comprises the ATG initiation gene of coding exon 1 through coding exon 5 of the human IL-4Ra gene, and the humanized IL-4Ra gene is operably linked to rodent IL-4Ra regulatory elements at the endogenous rodent IL-4Ra locus. 
Postupak dobivanja humaniziranog glodavca, naznačen time što se sastoji u zamjeni genomskog fragmenta gena za glodavački IL-4Ra na lokusu za endogeni glodavački IL-4Ra genomskim fragmentom gena za ljudski IL-4Ra kako bi se dobilo gen za humanizirani IL-4Ra koji sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, te kodirajuće egzone 6-9 gena za glodavački IL-4Ra, gdje genomski fragment gena za glodavački IL-4Ra sadrži početni kodon ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za glodavački IL-4Ra, a genomski fragment gena za ljudski IL-4Ra sadrži početni gen ATG kodirajućeg egzona 1 do kodirajućeg egzona 5 gena za ljudski IL-4Ra, gdje je gen za humanizirani IL-4Ra operativno povezan s regulacijskim elementim glodavačkog IL-4Ra na lokusu za endogeni glodavački IL-4Ra.
The method of claim 8, wherein the rodent is a mouse or a rat. 
Postupak u skladu s patentnim zahtjevom 8, naznačen time što je glodavac miš ili štakor.
The method of claim 8 or 9, wherein the rodent is a mouse. 
Postupak u skladu s patentnim zahtjevom 8 ili 9, naznačen time što je glodavac miš.
inducing skin inflammation in said rodent, administering an agent to said rodent, determining whether skin inflammation is reduced by the agent, and identifying the agent as a human specific IL-4 or IL-4Ra antagonist based on its ability to reduce skin inflammation. 
osiguravanja dvostruko humaniziranog IL-4 i IL-4Ra glodavca u skladu s patentnim zahtjevom 6, izazivanja upala kože kod navedenog glodavca, primjene sredstva na navedenom glodavcu, određivanja smanjuje li sredstvo upalu kože, te identificiranja sredstva kao ljudsko specifičnog antagonista IL-4 ili IL-4Ra na osnovi njegova sposobnost da smanji upalu kože.
Method for producing laminate floorboards with edges following the natural curvature of the timber planks, comprising steps, wherein: 
Postupak za proizvodnju višeslojnih podnih parketnih ploča s rubovima koji prate prirodnu zakrivljenost neobrađenih drvenih dasaka koji sadrži korake u kojima se:
Method according to claim 1, characterized in that plywood, fibreboard or chipboard are used as a substrate. 
Postupak prema zahtjevu 1, naznačen time, da se kao podloga koristi šperploča, vlaknasta ploča ili iverica.
Method according to any one of previous claims, characterized in that in step a) where the contour data of the veneer planks following natural curvature along with the images of veneer planks are scanned and recorded into the computer database, said data comprising additionally at least the data of the length, width, thickness and contour of the plank, data of the contour of bark, pith, heartwood and wane of the veneer planks and wood defects. 
Postupak prema bilo kojem od prethodnih zahtjeva, naznačen time, da u koraku a) gdje su podaci o rubovima konture prirodno zakrivljenih lamela zajedno s izgledima lamela skenirani i sačuvani u bazi podataka računala, navedeni podaci još sadrže barem podatke o duljini, širini, debljini i rubovima konture daske, informacije o kori, srži, bjeljici i lisičavosti lamela, te o oštećenjima drveta.
The pharmaceutical composition according to claim 4, for its use in the treatment of the deleterious effects in breast capsular contracture observed after the surgical implantation of breast implants in humans. 
Farmaceutski pripravak prema zahtjevu 4, naznačen time da je za uporabu za liječenje štetnih učinaka kod kapsularne kontrakture dojke primijećene nakon kirurške implantacije implantata za grudi kod ljudi.
Pirfenidone and silicium dioxide are screened through mesh 30 screen in the oscillating granulator and placed in the ribbon blender and mixed during 5 minutes; 
Pirfenidon i silicijev dioksid se prosijavaju kroz sito veličine u oscilirajućem granulatoru i postavljeni u vrpčastu miješalicu i miješani tijekom 5 minuta;
Microcrystalline cellulose, low viscosity hydroxypropylmethylcellulose (HPMC) and high viscosity hydroxypropylmethylcellulose (HPMC) are screened through mesh 30 screen in the oscillating granulator and placed in the ribbon blender of step 1 and mixed during 15 minutes; 
Mikrokristalna celuloza, hidroksipropilmetilceluloza (HPMC) niske viskoznosti i hidroksipropilmetilceluloza (HPMC) visoke viskoznosti se prosijavaju kroz sito broj 30 u oscilirajućem granulatoru i postavljeni su u vrpčastu miješalicu iz koraka 1 i miješani tijekom 15 minuta;
wherein the viral infection comprises: 
gdje virusna infekcija sadrži:
The compound for use according to claim 1, wherein the viral infection comprises a virus selected from the group consisting of viruses of the orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, and coronaviridae families. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu virusna infekcija sadrži virus odabran iz skupine koja se sastoji od virusa iz obitelji orthomyxoviridae, paramyxoviridae, arenaviridae, bunyaviridae, flaviviridae, filoviridae, togaviridae, picornaviridae, i coronaviridae.
The compound for use according to claim 1, wherein the viral infection is selected from the group consisting of adenovirus, Dengue fever, influenza A, influenza B, Junin, measles, parainfluenza, Pichinde, Punta Toro, respiratory syncytial, rhinovirus, Rift Valley Fever, SARS, Tacaribe, Venezuelan equine encephalitis, West Nile, and yellow fever viruses. 
Spoj za uporabu sukladno zahtjevu 1, pri čemu je virusna infekcija odabran iz skupine koja se sastoji od adenovirusa, virusa denga groznice, virusa influence A, virusa influence B, Junin virusa, virusa morbila, parainfluenca virusa, Pichinde virusa, Punta Toro virusa, respiratornog sincicijalnog virusa, rinovirusa, virusa groznice doline Rift, SARS virusa, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i virusa žute groznice.
The compound for use according to claim 3, wherein the viral infection is West Nile virus. 
Spoj za uporabu sukladno zahtjevu 3, pri čemu je virusna infekcija virus Zapadnog Nila.
The compound for use according to claim 3, wherein the viral infection is Dengue fever virus. 
Spoj za uporabu sukladno zahtjevu 3, pri čemu je virusna infekcija virus Denga groznice.
The compound for use according to claim 3, wherein the viral infection is Rift Valley Fever virus. 
Spoj za uporabu sukladno zahtjevu 3, pri čemu je virusna infekcija virus groznice doline Rift.
The compound for use according to claim 7, wherein the viral infection is Ebola virus. 
Spoj za uporabu sukladno zahtjevu 7, pri čemu je virusna infekcija Ebola virus.
The compound for use according to claim 7, wherein the viral infection is Marburg virus. 
Spoj za uporabu sukladno zahtjevu 7, pri čemu je virusna infekcija Marburg virus.
The compound for use according to claim 3, wherein the viral infection is yellow fever virus. 
Spoj za uporabu sukladno zahtjevu 7, pri čemu je virusna infekcija virus žute groznice.
The compound for use according to claim 7, wherein the viral infection is influenza A or influenza B virus. 
Spoj za uporabu sukladno zahtjevu 7, pri čemu je virusna infekcija virus influence A ili virus influence B.
The compound for use according to claim 12, wherein the RNA viral polymerase is a polymerase selected from the group consisting of Dengue fever, influenza A, influenza B, Junin, measles, parainfluenza, Pichinde, Punta Toro, respiratory syncytial, rhinovirus, Rift Valley Fever, SARS, Tacaribe, Venezuelan equine encephalitis, West Nile, and yellow fever viral polymerases. 
Spoj za uporabu sukladno zahtjevu 12, pri čemu je virusna RNK polimeraza polimeraza odabrana iz skupine koju čine virusne polimeraze virusa Denga groznice, virusa influence A, virusa influence B, Junin virusa, virusa ospica, parainfluenca virusa, Pichinde virusa, Punta Toro virusa, respiratornog sincicijalnog virusa, rinovirusa, virusa groznice doline Rift, SARS virusa, Takaribe virusa, virusa venecuelanskog konjskog encefalitisa, virusa Zapadnog Nila, i virusa žute groznice
The compound for use according to claim 13, wherein the RNA viral polymerase is West Nile, Dengue fever, or Rift Valley Fever viral polymerase. 
Spoj za uporabu sukladno zahtjevu 13, pri čemu je virusna RNK polimeraza virusna polimeraza virusa Zapadnog Nila, virusa denga groznice, ili virusa groznice doline Rift.